Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Geron ( (GERN) ) is now available.
On August 1, 2025, Geron Corporation’s Board of Directors appointed Harout Semerjian as the new President and CEO, effective August 7, 2025, replacing Dawn C. Bir. Mr. Semerjian brings extensive experience from his previous roles in the biotechnology and pharmaceutical sectors, including leadership positions at GlycoMimetics, Immunomedics, and Ipsen Pharma. The appointment is accompanied by an employment agreement that includes a substantial compensation package and stock options, reflecting the company’s strategic focus on strengthening its leadership team. Additionally, the company amended its severance plan and inducement award plan to align with these leadership changes, indicating a commitment to attracting and retaining top talent in the industry.
The most recent analyst rating on (GERN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Geron stock, see the GERN Stock Forecast page.
Spark’s Take on GERN Stock
According to Spark, TipRanks’ AI Analyst, GERN is a Neutral.
Geron’s overall stock score reflects significant financial challenges, with ongoing losses and negative cash flows weighing heavily. While the earnings call provided positive insights into revenue growth and strategic expansions, the technical indicators and valuation concerns highlight persistent market skepticism.
To see Spark’s full report on GERN stock, click here.
More about Geron
Average Trading Volume: 10,573,139
Technical Sentiment Signal: Sell
Current Market Cap: $764.3M
Learn more about GERN stock on TipRanks’ Stock Analysis page.